Consumer Testing for Disease Risk: ACOG Committee Opinion Summary, Number 816
- PMID: 33399425
- DOI: 10.1097/AOG.0000000000004201
Consumer Testing for Disease Risk: ACOG Committee Opinion Summary, Number 816
Abstract
With the increased emphasis on patient-driven health care and readily available access to patients as consumers through the internet and media, many genetic testing companies are marketing directly to consumers. Direct-to-consumer genetic testing may result in unique concerns and considerations, because of limited knowledge about available genetic tests among patients and health care professionals, challenges in interpretation of genetic test results, and lack of oversight of some companies, as well as issues of privacy and confidentiality. It is important to note that tests from different companies that evaluate the same condition or genes can vary greatly in scope and technical quality. When undergoing direct-to-consumer genetic testing, the consumer should be apprised of risk from screening or susceptibility test results that can neither prove nor eliminate disease potential but may be distressing for consumers. Because of these considerations and the fact that the interpretation of test results often requires specific training and medical knowledge, direct-to-consumer genetic testing ideally should be performed after counseling to review the test's potential benefits, risks, and limitations. Confirmatory genetic testing should be performed under the supervision of an appropriate obstetrician-gynecologist or other health care professional who is skilled in interpretation of genetic testing and risk assessment for the diseases of interest. This Committee Opinion has been updated to include information on counseling for patients who present with direct-to-consumer genetic test results, clinical vignettes, and an overview of currently available testing options as well as those potentially available in the near future.
Copyright © 2020 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
All ACOG committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on acog.org. For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.
Similar articles
-
Consumer Testing for Disease Risk: ACOG Committee Opinion, Number 816.Obstet Gynecol. 2021 Jan 1;137(1):e1-e6. doi: 10.1097/AOG.0000000000004200. Obstet Gynecol. 2021. PMID: 33399428
-
Committee Opinion No. 724 Summary: Consumer Testing for Disease Risk.Obstet Gynecol. 2017 Nov;130(5):1176-1177. doi: 10.1097/AOG.0000000000002395. Obstet Gynecol. 2017. PMID: 29064967
-
Committee Opinion No. 724: Consumer Testing for Disease Risk.Obstet Gynecol. 2017 Nov;130(5):e270-e273. doi: 10.1097/AOG.0000000000002401. Obstet Gynecol. 2017. PMID: 29064973
-
Evaluating Web-Based Direct-to-Consumer Genetic Tests for Cancer Susceptibility.JCO Precis Oncol. 2020 Mar 5;4:PO.19.00317. doi: 10.1200/PO.19.00317. eCollection 2020. JCO Precis Oncol. 2020. PMID: 34970636 Free PMC article. Review.
-
Ethical Issues Associated With Direct-to-Consumer Genetic Testing.Cureus. 2023 Jun 3;15(6):e39918. doi: 10.7759/cureus.39918. eCollection 2023 Jun. Cureus. 2023. PMID: 37404400 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources